Urology News and Research

Latest Urology News and Research

Reduced copayment policy has benefits all round

Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say.

18 Oct 2012

Health benefits of fibrate add-on detected postprandially

Adding fenofibrate to statin treatment significantly improves postprandial triglyceride response over statin treatment alone in individuals with diabetes, show findings from a US study.

18 Oct 2012

Botulinum treatment benefits in BPH maybe down to placebo effect

Treatment with botulinum toxin has proved no more effective than placebo at reducing symptoms in men with lower urinary tract symptoms due to benign prostate hyperplasia, show study findings.

17 Oct 2012

Stat5 protein could serve as biomarker to help guide prostate cancer treatment

Men who had high levels of the activated Stat5 protein in their prostate cancer after a radical prostatectomy were more likely to have a recurrence or die from the disease compared to men who had little to no presence of the growth protein, according to a recent study published in Human Pathology by Jefferson's Kimmel Cancer Center researchers.

17 Oct 2012

Study identifies multipotent and unipotent stem cells that contribute to prostate postnatal development

Publication in Nature Cell Biology advanced on line publication: researchers at the Université Libre de Bruxelles, ULB identify multipotent and unipotent Stem Cells (SCs) that contribute to prostate postnatal development.

16 Oct 2012

Hospital payments will soon be tied in part to patient satisfaction

The Wall Street Journal reports that, in the year ahead, nearly $1 billion in payments to hospitals will be based in part on patient satisfaction.

16 Oct 2012

Night work can increase risk of cancer in men

Night work can increase cancer risk in men, according to a new study published in the American Journal of Epidemiology by a research team from Centre INRS-Institut Armand-Frappier and Centre de recherche du Centre hospitalier de l'Universit- de Montr-al.

16 Oct 2012

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.

16 Oct 2012

White blood cell variation can help predict non-blood cancers

Postdoctoral Research Fellow Devin Koestler is a biostatistician in the Geisel School of Medicine at Dartmouth. He develops and applies statistical methods to large volumes of data, seeking new approaches for understanding disease, cancer in particular. Koestler and his colleagues are investigating the potential use of white blood cell variation as a diagnostic, predictive, and research tool in the study of non-blood cancers.

15 Oct 2012

Few physicians recommend active surveillance for low-risk prostate cancer

Few physicians recommend active surveillance for low-risk prostate cancer rather than pursuing surgery or radiation, according to a Mayo Clinic study being presented at the North Central Section of the American Urological Association's annual meeting Oct. 10-13 in Chicago.

15 Oct 2012

Scientists characterize unique model of bladder regeneration

While it is well known that starfish, zebrafish and salamanders can re-grow damaged limbs, scientists understand very little about the regenerative capabilities of mammals. Now, researchers at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine report on the regenerative process that enables rats to re-grow their bladders within eight weeks.

13 Oct 2012

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

The American Association for Cancer Research will host the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research at the Hilton Anaheim from Oct. 16-19, 2012.

12 Oct 2012

Reduced copayment policy has benefits all round

Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say.

11 Oct 2012

Theragenics enters second amended and restated credit agreement with Wells Fargo

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association.

11 Oct 2012

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

11 Oct 2012

USC project seeks to answer important questions about cancer

Three groups of University of Southern California (USC) researchers-representing medicine, chemistry and chemical engineering-are recipients of highly competitive grants from the National Institutes of Health's National Cancer Institute (NCI).

11 Oct 2012

Preoperative comorbidity indices predictive in bladder cancer

For patients with urothelial carcinoma of the bladder who are undergoing radical cystectomy, the measurement of preoperative comorbidity indices can improve prognostication in terms of cancer-independent mortality, study results show.

10 Oct 2012

UCSF project to explore mystery behind advanced prostate cancer

Many men survive prostate cancer, but thousands of others -- whose cancer spreads -- inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.

10 Oct 2012

PARP-1 plays a major role in controlling AR function in prostate cancer patients

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center researchers suggests.

10 Oct 2012

Mayo researchers discover new therapy for patients with neuromyelitis optica

Mayo Clinic researchers have identified a new therapy for patients with neuromyelitis optica that appears to stop inflammation of the eye nerves and spinal cord. NMO is a debilitating central nervous system disorder that is often misdiagnosed as multiple sclerosis (MS).

10 Oct 2012